{"product_id":"santen-bcg-matrix","title":"Santen Pharmaceutical Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSanten’s BCG Matrix preview shows where flagship ophthalmology products sit today, but the real leverage comes from the full report — quadrant-by-quadrant clarity, market share trends, and which assets deserve investment or pruning. Buy the full BCG Matrix for a ready-to-use Word report plus an Excel summary with data-backed recommendations you can present to leadership. Skip the guesswork and get strategic direction tailored to Santen’s portfolio—fast, actionable, and designed for decision-makers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal glaucoma Rx franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSanten’s global glaucoma Rx sits in BCG’s star quadrant: high share in a market still expanding as glaucoma prevalence rose from an estimated 76 million in 2020 toward projected 111.8 million by 2040, with the global glaucoma therapeutics market roughly $6.8 billion in 2024. Strong clinical footprint needs sustained promotion and market-access investment to defend advantage. The franchise is cash-hungry for lifecycle R\u0026amp;D and combo launches but, if held, should mature into a steady cash stream.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDry eye immunomodulator (EU\/Asia)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChronic dry eye is a growing mid-single-digit CAGR market, with global therapeutics valued around USD 3.9 billion in 2023; Santen’s immunomodulator holds leadership pockets in EU and Asia, capturing early high-value share. Reimbursement alignment and physician education require ongoing investment to unlock uptake. Once adoption crosses the tipping point, volumes ramp rapidly and strong adherence converts this franchise into a durable cash cow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePediatric VKC therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePediatric VKC therapy is a rare but fast-recognized unmet need with strong brand equity for Santen in key Asian and European markets; where launched it shows high share and double-digit growth potential. Ongoing HCP training and payer engagement are required to widen eligible use and uptake. Investment should focus on deepening penetration and market access before competitors scale. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePremium surgical devices \u0026amp; IOLs in Asia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAsia accounted for roughly half of global cataract procedures in 2024, about 10–12 million operations, with premium IOL mix rising toward 15% in key markets; Santen holds double-digit share in Japan and selected Southeast Asian markets, though exact national shares vary.\u003c\/p\u003e\n\u003cp\u003eSurgeon education and channel coverage require high OPEX, but the market growth curve and service-led repeat business make the segment attractive; continued field investment is critical to lock leadership.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024: Asia ~10–12M cataracts; premium IOL mix ~15%\u003c\/li\u003e\n\u003cli\u003eSanten: double-digit share in Japan and select SEA markets\u003c\/li\u003e\n\u003cli\u003eHigh spend on surgeon training and channel coverage\u003c\/li\u003e\n\u003cli\u003eService quality drives repeat sales; reinvest to sustain growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyopia management solutions (Asia growth)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChildhood myopia in East Asia reaches 50–90% in adolescents, and global myopia is projected to affect ~50% of people by 2050, driving payer\/parent demand; Santen’s early-mover clinical narratives and product mix position it as a Star in Asia for myopia management.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNeeds: co-marketing, school screening partnerships, clinician training\u003c\/li\u003e\n\u003cli\u003eUpside: large addressable market if scaled responsibly\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlaucoma \u003cstrong\u003e$6.8B\u003c\/strong\u003e, Dry eye \u003cstrong\u003e$3.9B\u003c\/strong\u003e; invest in Asia myopia\/VKC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSanten’s glaucoma Rx is a 2024 star (global glaucoma therapeutics ~$6.8B; prevalence 76M in 2020→111.8M by 2040), needing promotion and access spend. Chronic dry eye (~$3.9B in 2023) shows regional leadership; requires reimbursement push. VKC and myopia in Asia (adolescent myopia 50–90%) are high-growth stars; invest in training and partnerships.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024\/2023 Market\u003c\/th\u003e\n\u003cth\u003eSanten position\u003c\/th\u003e\n\u003cth\u003eKey need\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlaucoma\u003c\/td\u003e\n\u003ctd\u003e$6.8B (2024)\u003c\/td\u003e\n\u003ctd\u003eHigh share\u003c\/td\u003e\n\u003ctd\u003eAccess\/promotion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDry eye\u003c\/td\u003e\n\u003ctd\u003e$3.9B (2023)\u003c\/td\u003e\n\u003ctd\u003eLeadership pockets\u003c\/td\u003e\n\u003ctd\u003eReimbursement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise BCG Matrix review of Santen’s portfolio, noting Stars, Cash Cows, Question Marks, Dogs with investment and divestment guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Santen BCG Matrix that pinpoints underperformers and growth bets, ready for C-level sharing or slides\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJapan OTC lubricants \u0026amp; allergy drops\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJapan OTC lubricants and allergy drops are mature categories where Santen sustains dominant shelf presence and loyal users, supporting stable repeat purchases across retail and pharmacy channels. The Japanese OTC eye-care market is roughly JPY 100 billion in 2024, with Santen capturing a leading position that delivers high gross margins from scale and brand familiarity. Promotional spend is modest, enabling low burn and steady cash generation. Continue milking the line while optimizing supply and retail mix to preserve margin and turnover.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished antibiotic\/anti-inflammatory combos\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEstablished antibiotic\/anti-inflammatory combos supply stable demand around surgeries and acute care, showing limited growth but retaining high market share with predictable hospital tender orders. Minimal detailing beyond stewardship messaging keeps promotion costs low. These products generate steady cash flow that funds Santen’s R\u0026amp;D and next-growth bets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy glaucoma drops (home market)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegacy glaucoma drops in Santen’s home market remain cash cows: strong brand trust and habitual prescribing keep volumes steady despite low-single-digit category growth (≈1–3% in 2024). Price and generic pressure are contained by a large installed patient base, preserving unit volumes. Manufacturing efficiencies sustain healthy margins and free cash; maintain access and avoid distractions to keep cash flowing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConventional IOL portfolio (mature tiers)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eConventional IOL portfolio delivers large, steady volume in non-premium segments driven by procurement channels; Santen’s supply reliability sustains share despite low price elasticity. Operational excellence preserves margins through scale and cost control, enabling incremental product upgrades rather than major R\u0026amp;D or marketing spend. This line acts as a cash cow funding innovation elsewhere.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-volume, low-price segment\u003c\/li\u003e\n\u003cli\u003eProcurement-driven purchasing\u003c\/li\u003e\n\u003cli\u003eShare maintained by supply reliability\u003c\/li\u003e\n\u003cli\u003eStable margins via efficiency\u003c\/li\u003e\n\u003cli\u003eIncremental upgrades, low capex\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContact lens care solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eContact lens care solutions are classic cash cows for Santen: stable, everyday-use SKUs with sticky consumer habits and low innovation needs, supported by strong pharmacy and optical distribution; global contact lens solutions market estimated at USD 2.7bn in 2024 with ~4.2% CAGR. Cash-positive with limited promotional spend, focus is on optimizing assortment, protecting shelf space and banking steady profits.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable demand\u003c\/li\u003e\n\u003cli\u003eLow R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003eStrong distribution\u003c\/li\u003e\n\u003cli\u003eProtect shelf \u0026amp; assort\u003c\/li\u003e\n\u003cli\u003eUSD 2.7bn market 2024, ~4.2% CAGR\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-margin Japan OTC and contact lens care fund R\u0026amp;D: \u003cstrong\u003eJPY 100bn\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSanten’s Japan OTC eye-care (≈JPY 100bn 2024) and contact lens care (global USD 2.7bn 2024, ~4.2% CAGR) plus legacy glaucoma (growth ≈1–3% 2024) and conventional IOLs deliver steady, high-margin cash flow via scale, supply reliability and low promo\/R\u0026amp;D spend; proceeds fund R\u0026amp;D and growth bets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 Size\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eJapan OTC eye-care\u003c\/td\u003e\n\u003ctd\u003eJPY 100bn\u003c\/td\u003e\n\u003ctd\u003eHigh margin, stable\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContact lens care\u003c\/td\u003e\n\u003ctd\u003eUSD 2.7bn\u003c\/td\u003e\n\u003ctd\u003e4.2% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlaucoma\/IOLs\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003eLow growth, steady cash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eSanten Pharmaceutical BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing here is the exact Santen Pharmaceutical BCG Matrix you'll receive after purchase. No watermarks, no placeholders—just a fully formatted, analysis-ready report built for strategic clarity. Once bought, the same document is instantly downloadable and editable for presentations or planning. It’s the final product, crafted by experts and ready to use—no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56164185670009,"sku":"santen-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/santen-bcg-matrix.png?v=1762726894","url":"https:\/\/portersfiveforce.com\/products\/santen-bcg-matrix","provider":"Porter's Five Forces","version":"1.0","type":"link"}